Table 2. CAR clinical trials by target antigen.
| Antigen | Signaling and accessory |
Cell typea |
Delivery methodb |
Disease(s) | Primary institution(s) |
Phase(s) | Enrollment | NCT #c |
|---|---|---|---|---|---|---|---|---|
| BCMA | 41BBz | T cells | NA | MM | UPenn | Phase 0 | 30 | NCT02546167 |
| BCMA | 41BBz | T cells | Lenti | MM | bluebird bio | Phase 1 | 50 | NCT02658929 |
| BCMA | 41BBz | T cells | Lenti | MM | bluebird bio | 50 | NCT02786511 | |
| CD7 | CD28-41BBz | NK-92 | NA | AML | PersonGen | Phase1,2 | 10 | NCT02742727 |
| CD19 | 41BBz | T cells | Retro | B-ALL, B-CLL, B-NHL | UPenn | 110 | NCT01029366 | |
| CD19 | 41BBz | T cells (allo) | Lenti | B-ALL | UPenn | Phase 1 | 10 | NCT01551043 |
| CD19 | 41BBz | T cells | Lenti | B-ALL, B-CLL, B-NHL | UPenn | Phase 1 | 20 | NCT01626495 |
| CD19 | 41BBz | T cells | Lenti | B-CLL, B-SLL | UPenn | Phase 2 | 65 | NCT01747486 |
| CD19 | 41BBz | T cells 1:1 CD4+ and CD8+ | Lenti | B-ALL | Seattle Children's | Phase1,2 | 80 | NCT02028455 |
| CD19 | 41BBz | T cells | Lenti | B-NHL | UPenn | Phase 2 | 51 | NCT02030834 |
| CD19 | 41BBz | T cells | Lenti | B-ALL | UPenn | Phase 2 | 24 | NCT02030847 |
| CD19 | 41BBz | T cells | RNA (electro) | HL | UPenn | Phase 0 | 16 | NCT02277522 |
| CD19 | 41BBz | T cells | Lenti | B-NHL | Novartis | Phase 2 | 100 | NCT02445248 |
| CD19 | 41BBz | T cells | RNA (electro) | HL | UPenn|CHOP | Phase 0 | 10 | NCT02624258 |
| CD19 | 41BBz | T cells | Lenti | B-CLL, B-SLL | UPenn | 15 | NCT02640209 | |
| CD19 | 41BBz | T cells | Lenti | B-NHL | UPenn | Phase1,2 | 12 | NCT02650999 |
| CD19 | 41BBz | T cells | Lenti | B-CLL | Shanghai GeneChem | Phase1,2 | 30 | NCT02672501 |
| CD19 | 41BBz | T cells | Lenti | MM | UPenn | Phase 2 | 25 | NCT02794246 |
| CD19 | 41BBz and zeta-only | T cells | Retro | B-ALL, B-CLL, B-NHL | Chinese PLAGH | 12 | NCT01864889 | |
| CD19 | 41BBz and zeta- only | T cells | Retro | B-NHL | Chinese PLAGH | Phase1,2 | 2 | NCT02081937 |
| CD19 | 41BBz,CD20/34t | T cells (allo, gen mod) | Lenti | B-ALL, B-CLL, B-NHL | Servier | 200 | NCT02735083 | |
| CD19 | 41BBz,CD20/34t | T cells (allo, gen mod) | Lenti | B-ALL, B-CLL | Servier | Phase 1 | 12 | NCT02746952 |
| CD19 | 41BBz,EGFRt | T cells | Lenti | B-ALL, B-CLL, B-NHL | FHCRC|NCI | Phase1,2 | 145 | NCT01865617 |
| CD19 | 41BBz,EGFRt | T cells | Lenti | B-NHL | Juno | Phase 1 | 70 | NCT02631044 |
| CD19 | 41BBz,EGFRt | T cells | Lenti | B-NHL | FHCRC|NCI|Juno MedImmune AstraZeneca | Phase 1 | 42 | NCT02706405 |
| CD19 | CD27z,iCasp9 | T cells | Lenti | B-NHL | PKU|UF | Phase1,2 | 20 | NCT02247609 |
| CD19 | CD28-41BBz | T cells | Retro | B-CLL, B-NHL | Uppsala Univ. | Phase1,2 | 15 | NCT02132624 |
| CD19 | CD28-41BBz,EGFRt | CMV or EBV Tcm cells (allo) | NA | B-ALL, B-CLL, B-NHL | FHCRC\\NCI | Phase1,2 | 1 | NCT01475058 |
| CD19 | CD28z | T cells | Retro | B-NHL | NCI\NIHCC | Phase 1 | 43 | NCT00924326 |
| CD19 | CD28z | T cells | NA | B-ALL | MSKCC | Phase 1 | 60 | NCT01044069 |
| CD19 | CD28z | T cells (allo) | Virus | B-ALL, B-CLL, B cell lymphomas | NCI\NIHCC | Phase 1 | 42 | NCT01087294 |
| CD19 | CD28z | T Cells | Transpos (electro) | B-NHL | M.D. Anderson Intrexon|Ziopharm | Phase 1 | 60 | NCT00968760 |
| CD19 | CD28z | EBV-CTLs (allo) | NA | B-ALL, B-NHL | MSKCC | Phase 1 | 12 | NCT01430390 |
| CD19 | CD28z | T Cells (allo) | Transposon (electro) | B-ALL, B-CLL, B-NHL | M.D. Anderson Intrexon|Ziopharm | Phase 1 | 140 | NCT01497184 |
| CD19 | CD28z | T cells | Retro | B-ALL, B-NHL | NCI\NIHCC | Phase 1 | 52 | NCT01593696 |
| CD19 | CD28z | T cells | NA | B-ALL, B-CLL, B-NHL | M.D. Anderson ZiopharmIIntrexon | Phase 1 | 30 | NCT02529813 |
| CD19 | CD28z | T cells | NA | B-NHL | MSKCC | Phase 1 | 17 | NCT01840566 |
| CD19 | CD28z | T cells | NA | B-ALL | MSKCC|Dana-Farber | Phase 1 | 24 | NCT01860937 |
| CD19 | CD28z | T cells (allo) | Retro | B-ALL, B-CLL, B-NHL | Baylor | Phase 1 | 40 | NCT02050347 |
| CD19 | CD28z | T cells | Retro | B-NHL | Jichi Med. Univ.|Takara | Phase1,2 | 18 | NCT02134262 |
| CD19 | CD28z | T cells | Retro | B-NHL | Kite Pharma | Phase1,2 | 124 | NCT02348216 |
| CD19 | CD28z | T cells | Retro | B-ALL | Juno | Phase 2 | 90 | NCT02535364 |
| CD19 | CD28z | T cells | Retro | B-NHL | Kite Pharma | Phase 2 | 70 | NCT02601313 |
| CD19 | CD28z | T cells | Retro | B-ALL | Kite Pharma | Phase1,2 | 75 | NCT02614066 |
| CD19 | CD28z | T cells | Retro | B-ALL | Kite Pharma | Phase1,2 | 75 | NCT02625480 |
| CD19 | CD28z | T cells | Retro | B-NHL | Xuzhou Med. College | Phase1,2 | 20 | NCT02652910 |
| CD19 | CD28z | T cells | Retro | B-ALL | Juno | 500 | NCT02813252 | |
| CD19 | CD28z | T cells | Retro | B-ALL, B-NHL | Sheba Med. Center | Phase1,2 | 40 | NCT02772198 |
| CD19 | CD28z and 41BBz | T cells | Lenti | B-ALL | AMMS|PKU | Phase 1 | 5 | NCT02186860 |
| CD19 | CD28z and 41BBz | T cells | NA | B-ALL, B-CLL, B-NHL | Xuzhou Med. College | Phase1,2 | 20 | NCT02685670 |
| CD19 | CD28z and CD28-41BBz | T cells | Retro | B-ALL, B-CLL, B-NHL | Baylor | Phase 1 | 14 | NCT01853631 |
| CD19 | CD28z and zeta-only | Tcm-enriched T cells | Lenti | B-NHL | City of Hope|NCI | Phase1,2 | 57 | NCT01318317 |
| CD19 | CD28z,EGFRt | T cells | Lenti | B-ALL | Seattle Children's | Phase 1 | 18 | NCT01683279 |
| CD19 | CD28z,EGFRt | T cells Tcm or Tn,Tnem | Lenti | B-ALL | City of Hope|NCI | Phase 1 | 48 | NCT02146924 |
| CD19 | CD28z,undefined safety switch | T cells | Retro or Lenti | B-ALL, B-CLL, B-NHL | Shenzhen Second People's Hospital | Phase 1 | 36 | NCT02456350 |
| CD19 | NA | T cells | NA | B-ALL, B-CLL, B-NHL | Southwest Hospital, China | Phase1,2 | 45 | NCT02349698 |
| CD19 | NA | T cells | NA | B-ALL, B-CLL, B-NHL | ICT | 30 | NCT02813837 | |
| CD19 | NA | T cells | Lenti | B-ALL, B-CLL, B-NHL | Tongji Univ. Med. | Phase1,2 | 40 | NCT02537977 |
| CD19 | NA | T cells | NA | B-CLL | SMMU | Phase1,2 | 20 | NCT02644655 |
| CD19 | NA | T cells (allo) | NA | B-ALL | AMMS|Chinese PLAGH | Phase 1 | 10 | NCT02799550 |
| CD19 | NA | T cells | NA | B-NHL | Sinobioway Cell Therapy | Phase1,2 | 24 | NCT02728882 |
| CD19 | NA | T cells | NA | B-ALL | Sinobioway Cell Therapy | Phase1,2 | 24 | NCT02735291 |
| CD19 | NA | T cells | NA | B-NHL | Univ. College, London | Phase 1 | 12 | NCT02431988 |
| CD19 | NA | T cells | NA | B-ALL, B-CLL, B-NHL | Beijing Doing Biomed. | Phase 1 | 100 | NCT02546739 |
| CD19 | NA | YδT-cells (allo) | NA | B-ALL, B-CLL, B-NHL | Beijing Doing Biomed. | Phase 1 | 48 | NCT02656147 |
| CD19 | NA | T cells | Retro | B-ALL, B-CLL, B-NHL | NCI|NIHCC | Phase 1 | 64 | NCT02659943 |
| CD19 | NA | T cells | NA | B-ALL | Guangdong General Hospital|CAS | Phase 1 | 30 | NCT02822326 |
| CD19 | NA | T cells | NA | B-ALL, B-NHL | Univ. College, London | Phase 1 | 18 | NCT02443831 |
| CD19 | NA | T cells | NA | B-CLL | iCarTAB Xuzhou Med. | Phase1,2 | 50 | NCT02782351 |
| CD19 | NA | T cells | NA | B-NHL | PKU|Marino | Phase 1 | 20 | NCT02842138 |
| CD19 | NA | T cells | NA | B-ALL, B-CLL, B-NHL | PersonGen | Phase1,2 | 10 | NCT02851589 |
| CD19 | NA | T cells | NA | B-ALL, B-CLL, B-NHL | PersonGen | Phase1,2 | 10 | NCT02819583 |
| CD19 | zeta-only | T cells | Retro | B-NHL | Christie NHS Foundation | Phase 1 | 24 | NCT01493453 |
| CD19, CD20 | NA | T cells | NA | B-NHL | Southwest Hospital, China | Phase1,2 | 40 | NCT02737085 |
| CD19, Mesothelin | 41BBz | T cells | Lenti | Pancreatic Cancer | UPenn\UCSF | Phase 1 | 12 | NCT02465983 |
| CD20 | NA | T cells | Virus | B-ALL, B-CLL, B-NHL | Southwest Hospital, China | Phase1,2 | 45 | NCT02710149 |
| CD22 | 41BBz | T cells | Lenti | B-ALL, B-NHL | NCI|NIHCC | Phase 1 | 57 | NCT02315612 |
| CD22 | 41BBz | T cells | Lenti | B-ALL | UPenn | 15 | NCT02588456 | |
| CD22 | 41BBz | T cells | Lenti | B-ALL | UPenn|CHOP | Phase 1 | 15 | NCT02650414 |
| CD22 | 41BBz | T cells | Retro | B-NHL | Xuzhou Med. | Phase 1 | 20 | NCT02721407 |
| CD22 | NA | T cells | Virus | B-ALL, B-CLL, B-NHL | iCarTAB|Xuzhou Med. | Phase1,2 | 10 | NCT02794961 |
| CD30 | CD27z,iCasp9 | T cells | Lenti | HL, B-NHL | PKU|UF | Phase1,2 | 20 | NCT02274584 |
| CD30 | CD28z | T cells | Virus | HL, B-NHL | UNC Lineberger|Baylor | Phase 1 | 18 | NCT01316146 |
| CD30 | CD28z | T cells | Virus | HL, B-NHL | UNC Lineberger | Phase 1 | 18 | NCT02663297 |
| CD30 | CD28z | T cells | Virus | HL, B-NHL | UNC Lineberger | Phase1,2 | 31 | NCT02690545 |
| CD30 | NA | T cells | NA | HL, B-NHL | Chinese PLAGH | Phase1,2 | 30 | NCT02259556 |
| CD33 | 41BBz and zeta-only | T cells | Retro | AML | Chinese | Phase1,2 | 10 | NCT01864902 |
| CD33 | 41BBz and zeta-only | T cells | Retro | AML | AMMS|Chinese PLAGH | Phase 1 | 12 | NCT02799680 |
| CD70 | NA | T cells | Retro | CD70+ cancers | NCI|NIHCC | Phase1,2 | 113 | NCT02830724 |
| CD123 | 41BBz | T cells | RNA (electro) | AML | UPenn | Phase 0 | 7 | NCT02623582 |
| CD123 | CD28z,EGFRt | T cells | Lenti | AML | City of Hope NCI | Phase 1 | 30 | NCT02159495 |
| CD133 | 41BBz and zeta-only | T cells | Retro | AML, B-ALL, various solid tumors | Chinese PLAGH | Phase 1 | 20 | NCT02541370 |
| CD138 | 41BBz and zeta-only | T cells | Retro | MM | Chinese PLAGH | Phase1,2 | 10 | NCT01886976 |
| CD171 | CD28-41BBz,EGFRt and 41BBz,EGFRt | T cells 1:1 CD4+ and CD8+ | Lenti | Neuroblastoma | Seattle Children's | Phase 1 | 80 | NCT02311621 |
| CEA | CD28z | T cells | NA | Various solid tumors | Roger Williams | Phase 2 | 48 | NCT01723306 |
| CEA | NA | T cells | NA | Various solid tumors | Southwest Hospital, China | Phase 1 | 75 | NCT02349724 |
| CEA | zeta-only | T cells | Retro | Various solid tumors | Cancer Research UK | Phase 1 | 14 | NCT01212887 |
| EGFR | 41BBz and zeta-only | T cells | Lenti | EGFR+ Solid Tumors | Chinese PLAGH | Phase1,2 | 60 | NCT01869166 |
| EGFRvIII | 41BBz | T cells | Lenti | Glioma | UPenn|UCSF | 12 | NCT02209376 | |
| EGFRvIII | 41BBz | T cells | Lenti | Glioblastoma | UPenn | 8 | NCT02666248 | |
| EGFRvIII | CD28-41BBz | T cells | Retro | Glioma | NCI|NIHCC | Phase1,2 | 18 | NCT01454596 |
| EGFRvIII | NA | T cells | Lenti | Glioma | RenJi Hospital | Phase 1 | 10 | NCT02331693 |
| EGFRvIII | NA | T cells | Retro | Glioblastoma | Duke Univ. | Phase 1 | 48 | NCT02664363 |
| EGFRvIII | NA,EGFRt | T cells | Lenti | Glioblastoma | Beijing Sanbo Marino | Phase 1 | 20 | NCT02844062 |
| EPCAM | NA | T cells | NA | Stomach Neoplasms | Sinobioway | Phase1,2 | 19 | NCT02725125 |
| EPCAM | NA | T cells | NA | Liver Neoplasms | Sinobioway | Phase1,2 | 25 | NCT02729493 |
| EPHA2 | NA | T cells | NA | Glioma | Fuda, Guangzhou | Phase1,2 | 60 | NCT02575261 |
| ErbB dimers | CD28z,4aβ | T cells | Retro | Head and Neck Cancer | King's College | Phase 1 | 30 | NCT01818323 |
| FAP | CD28z | CD8+ T cells | Retro | Mesothelioma | Univ. of Zurich | Phase 1 | 6 | NCT01722149 |
| GD2 | CD28-41BB-CD27z,iCasp9 | T cells | Lenti | Neuroblastoma | Zhujiang Hospital | Phase 2 | 30 | NCT02765243 |
| GD2 | CD28- | T cells | Retro | Neuroblastoma | Baylor|NCI | Phase 1 | 11 | NCT01822652 |
| GD2 | CD28-OX40z,iCasp9 | NK T cells | Retro | Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma | NCI|NIHCC | Phase 1 | 72 | NCT02107963 |
| GD2 | CD28-OX40z,iCasp9 | VZV T cells | Retro | Sarcomas | Baylor|NCI | Phase 1 | 26 | NCT01953900 |
| GD2 | CD28-OX40z,iCasp9 | NK T cells | Retro | Neuroblastoma | Baylor | Phase 1 | 18 | NCT02439788 |
| GD2 | CD28z | T cells | Virus | Neuroblastoma | Cancer Research UK | Phase 1 | 27 | NCT02761915 |
| GD2 | NA | triVirus-CTLs (allo) | Retro | Neuroblastoma | Children's Mercy, KC | Phase 1 | 5 | NCT01460901 |
| GPC3 | 41BBz | T cells | Virus | Hepatocellular Carcinoma | Shanghai GeneChem | Phase1,2 | 30 | NCT02715362 |
| GPC3 | CD28-41BBz | T cells | Virus | Hepatocellular Carcinoma | RenJi Hospital | Phase 1 | 20 | NCT02395250 |
| GPC3 | NA | T cells | NA | Hepatocellular Carcinoma | Fuda, Guangzhou | Phase1,2 | 60 | NCT02723942 |
| HER2 | 41BBz and zeta-only | T cells | Virus | HER-2+ Solid Tumors | Chinese PLAGH | Phase1,2 | 10 | NCT01935843 |
| HER2 | CD28z | T cells | Virus | Sarcoma | Baylor | Phase 1 | 36 | NCT00902044 |
| HER2 | CD28z | CMV T cells | Virus | Glioblastoma | Baylor | Phase 1 | 16 | NCT01109095 |
| HER2 | CD28z | T cells | Retro | Breast Cancer | Fuda, Guangzhou | Phase1,2 | 60 | NCT02547961 |
| HER2 | CD28z | T cells | Virus | Glioblastoma | Baylor | Phase 1 | 14 | NCT02442297 |
| HER2 | CD28z,TGFβDN | EBV T cells | Retro | HER2+ Malignancies | Baylor | Phase 1 | 19 | NCT00889954 |
| HER2 | NA | T cells | NA | Various solid tumors | Southwest Hospital, China | Phase1,2 | 60 | NCT02713984 |
| IL-1-RAP | NA | NA | NA | CML | Univ. Hospital of Besancon | 40 | NCT02842320 | |
| IL-13R | 41BBz,CD19t | T cells Tcm-enriched | Lenti | Glioma | City of Hope|NCI | Phase 1 | 75 | NCT02208362 |
| Kappa | CD28z | T cells | Retro | B-CLL, B-NHL | Baylor | Phase 1 | 54 | NCT00881920 |
| LeY | CD28z | T cells | Retro | MM, AML, MDS | Peter MacCallum | Phase 1 | 6 | NCT01716364 |
| Mesothelin | 41BBz | T cells | RNA (electro) | Mesothelioma | Upenn | Phase 1 | 18 | NCT01355965 |
| Mesothelin | 41BBz | T cells | Lenti | Various solid tumors | UPenn | Phase 1 | 21 | NCT02159716 |
| Mesothelin | 41BBz | T cells | Lenti | Various solid tumors | UPenn | 50 | NCT02388828 | |
| Mesothelin | 41BBz | T cells | Retro | Various Mesothelin+ Tumors | Chinese PLAGH | Phase 1 | 20 | NCT02580747 |
| Mesothelin | 41BBz | T cells | Virus | Pancreatic Cancer | Shanghai GeneChem | Phase 1 | 30 | NCT02706782 |
| Mesothelin | CD28-41BBz | T cells | Retro | Various solid tumors | NCI|NIHCC | Phase1,2 | 15 | NCT01583686 |
| Mesothelin | CD28z-iCasp9 | T cells | Virus | Mesothelioma, Lung and Breast Cancers | MSKCC | Phase 1 | 24 | NCT02414269 |
| Mesothelin | NA | T cells | Virus | Breast Cancer | MSKCC | Phase 1 | 24 | NCT02792114 |
| MUC1 | CD28-41BBz | T cells | Virus | Various solid tumors | PersonGen | Phase1,2 | 20 | NCT02587689 |
| MUC1 | CD28-41BBz | T cells | Virus | Glioma, colorectal, gastric | PersonGen | Phase1,2 | 20 | NCT02617134 |
| MUC1 | NA | pNK cells | NA | Various solid tumors | PersonGen | Phase1,2 | 10 | NCT02839954 |
| MUC16 | CD28zfIL-12 | T cells | NA | Ovarian Cancer | MSKCC | Phase 1 | 30 | NCT02498912 |
| NKG2D | NA | T cells | Virus | AML, Myelodysplastic Syndrome, MM | Celdara Med. | Phase 1 | 21 | NCT02203825 |
| PSCA | zeta-only, iCD40/MyD88 | T cells | Retro | Pancreatic Cancer | Bellicum | Phase 1 | 30 | NCT02744287 |
| PSMA | CD28z | T cells | Retro | Prostate Cancer | Roger Williams | Phase 1 | 18 | NCT00664196 |
| PSMA | CD28z | T cells | Virus | Prostate Cancer | MSKCC | Phase 1 | 18 | NCT01140373 |
| ROR1 | 41BBz | T cells | NA | B-ALL, B-CLL, B-NHL, Various solid tumors | FHCRC|NCI | Phase 1 | 60 | NCT02706392 |
a
Unless specified cells are autologous patient-derived cells.
b
”Virus” indicates that the trial description mentions introducing the CAR by viral transduction but does not specify the kind of virus used.
c
Trials with recruitment listed as “Completed,” “Active but not recruiting,” “Terminated” or “Suspended” on clinicaltrails.gov are italicized. Trials were obtained by bulk data download from clinicaltrials.gov on August 1st 2016.